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Abstract 
Being able to self-renew and differentiate into virtually all cell types, both human embryonic 
stem cells (hESCs) and induced pluripotent stem cells (iPSCs) have exciting therapeutic im-
plications for myocardial infarction, neurodegenerative disease, diabetes, and other disorders 
involving irreversible cell loss. However, stem cell biology remains incompletely understood 
despite significant advances in the field. Inefficient stem cell differentiation, difficulty in verifying 
successful delivery to the target organ, and problems with engraftment all hamper the tran-
sition from laboratory animal studies to human clinical trials. Although traditional histo-
pathological techniques have been the primary approach for ex vivo analysis of stem cell be-
havior,  these  postmortem  examinations  are  unable  to  further  elucidate  the  underlying 
mechanisms in real time and in vivo. Fortunately, the advent of molecular imaging has led to 
unprecedented progress in understanding the fundamental behavior of stem cells, including 
their survival, biodistribution, immunogenicity, and tumorigenicity in the targeted tissues of 
interest. This review summarizes various molecular imaging technologies and how they have 
advanced the current understanding of stem cell survival, biodistribution, immunogenicity, and 
tumorigenicity. 
Key words: molecular imaging, stem cell therapy, survival, biodistribution, immunogenicity, tu-
morigenicity 
1. Introduction 
Human  embryonic  stem  cells  (hESCs)  and  in-
duced  pluripotent  stem  cells  (iPSCs)  possess  great 
potential  for  regenerative  medicine  owing  to  their 
pluripotency  and  capacity  for  self-renewal.  For  in-
stance, dopaminergic neurons derived from iPSCs [1] 
and  ESCs  [2]  have  been  used  to  improve  clinical 
symptoms of Parkinson’s disease in the mouse model. 
Stem cells have also been differentiated into chron-
drocytes to repair osteoarthritis [3], into cardiomyo-
cytes to mitigate ischemic heart disease [4-6], and into 
insulin  producing  cells  to  potentially  treat  diabetes 
[7]. Transitioning from animal studies to humans has 
showcased the great promise of stem cell therapy, but 
has also exposed unanswered questions such as how 
effectively  stem  cells  can  migrate,  engraft,  and  dif-
ferentiate, and what risks tumorigenicity and immune 
rejection could pose to the patient. Over the last dec-
ade, advances in molecular imaging have allowed a 
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deeper understanding of the in vivo behavior of stem 
cells and have proven to be indispensible in preclini-
cal and clinical studies.  
There are two main classes of molecular imaging 
techniques: direct stem cell labeling and reporter-gene 
imaging (Fig. 1). The former employs contrast agents 
such as magnetic particles, luminescent nanoparticles, 
or radionuclides to directly label the cell, whereas the 
latter  genetically  alters  the  cell  to  transcribe  and 
translate a reporter protein. While direct labeling is 
both  straightforward  to  implement  and  commonly 
used, the contrast signal is diluted with each cellular 
division and the technique cannot distinguish viable 
cells from dead cells [8]. Reporter-genes, on the other 
hand, are only expressed by live cells and the signal is 
propagated by daughter cells [9]. However, reporter 
gene imaging requires transfection of genetic material 
using  plasmids,  retroviral,  or  viral  vectors,  which 
raises the concern of insertional mutagenesis and may 
necessitate  the  use  of  apoptosis-inducing  “suicide 
genes” before possible future use in the clinic [10, 11]. 
This  review  will  discuss  current  molecular  imaging 
techniques and how they have advanced present un-
derstanding  of  stem  cell  survival,  biodistribution, 
immunogenicity, and tumorigenicity. 
 
 
Figure 1: a. Direct imaging involves the labeling of stem cells with MRI or PET tracers ex vivo. Common tracers include SPIOs for MRI and 
111Indium Oxine for PET imaging. b. Indirect imaging involves the expression of reporter genes that encode a reporter protein, which in 
turn metabolizes a substrate that produces a detectable signal. 
 
 
2. Direct Iron Particle Labeling  
As one of the first imaging modalities for moni-
toring pluripotent stem cells  in vivo, magnetic reso-
nance imaging (MRI) offers high spatial and temporal 
resolution to obtain detailed morphological and func-
tional information. It requires the uptake of a contrast 
agent by the stem cell, the most common of which are 
superparamagnetic  iron  oxide  (SPIO)  nanoparticles. 
SPIOs can induce changes in T2 relaxivity at nano-
molar concentrations [12], and many formulations are 
FDA-approved for clinical applications [13]. There are 
two main methods by which stem cells can be directly 
labeled  by  SPIOs.  One  method,  magnetoporation, 
involves  the  coating  of  anionic  SPIOs  with  cationic 
transfection  agents  such  as  protamine  sulfate  or 
poly-L-lysine  [14].  Stem  cells  subsequently  endocy-
tose  the  resulting  complex  during  incubation  for 
around 24-48 hours [15]. Although many studies have 
shown that magnetoporation does not affect cell via-
bility  or  function  at  low  doses  [15-17],  there  is  evi-
dence that high doses can inhibit mesenchymal stem 
cell  (MSC)  migration  and  colony  formation  ability 
[18].  Another  study  showed  inhibition  of  chondro-
genesis in MSCs after FDA-approved Feridex labeling 
[19].  The  second  method,  magnetoelectroporation, 
uses low voltage pulses to induce endocytosis of SPIO 
particles. It works much more rapidly than magne-
toporation and is likewise relatively innocuous to the 
cell at lower doses [20].  
Several groups have shown the use of SPIOs for 
non-invasive MRI of neural stem cell migration, en-
graftment, and morphological differentiation [21, 22]. 
The contrast signals in these studies were detected for 
up to six weeks and the stem cells retained the ability 
to  proliferate  and  differentiate.  Other  groups  have 
shown that MRI can be used to track MSCs in cardiac 
repair  after  myocardial  infarction  [14,  23].  Here  the 
signals could be detected long term for three to eight 
weeks. However, one disadvantage inherent to both 
SPIO labeling methods is their inability to distinguish 
viable cells from dead cells or from scavenging mac-
rophages. This is due to the contrast material linger-Theranostics 2012, 2(4) 
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ing in the transplanted cells even after the cells have 
died, or because the SPIO particles may be absorbed 
by macrophages responsible for removing dead cells 
[9]. Moreover, T2 contrast agents such as SPIOs in-
duce hypointensities  on a T1 weighted  map, which 
can be misinterpreted as blood clots or hemhorrage in 
certain situations [24]. Fortunately, manganese based 
reagents  may  help  overcome  both  limitations.  For 
example, manganese chloride can only enter live cells 
through  the  voltage-gated  calcium  channel  and  has 
been used to assess the viability of both human ESCs 
and  bone  marrow  stromal  cells  in  vitro  [25,  26]. 
Moreover,  all  manganese  based  reagents,  including 
manganese  oxide  (MnO)  nanoparticles,  induce  T1 
hyperintensities and therefore reduce clinical confu-
sion [24]. MnO nanoparticles have been used to label 
and track MSCs in mice and to image gliblastomas in 
vivo [27, 28].  
3. Direct Radionuclide Imaging 
The advantages of radioscintigraphic techniques 
include their picomolar sensitivity, good tissue pene-
tration, and translation to clinical applications [8]. In 
fact, radionuclide imaging is the sole direct labeling 
technique used thus far in human studies, involving 
both autologous bone marrow-derived stem cells [29] 
and peripheral hematopoietic stem cells [30-32]. There 
are  two  main  techniques  for  radionuclide  imaging: 
positron emission tomography (PET) and single pho-
ton emission computed tomography (SPECT). SPECT 
tracers directly emit a gamma ray in one direction, in 
contrast to PET tracers, which send two gamma rays 
in opposite directions and thus possess coincidence 
detection with a higher spatial resolution. However, 
SPECT  is  generally  less  expensive  due  to  its  long-
er-lived and more readily available radioisotopes.  
The  most  widely  used  PET  isotopes  are  fluo-
rine-18 (18F), which has a half-life of 110 minutes, and 
copper-64 (64Cu), which has a much longer half-life of 
12.7 hours [33]. 18F is incorporated into a radiolabeled 
glucose  analog,  2-deoxy-2—18F-fluoro-D-glucose 
(18F-FDG), with the radioactive 18F substituted for the 
hydroxyl group at the 2’ position. Upon phosphory-
lation  by  hexokinase,  18F-FDG  remains  in  the  intra-
cellular  space.  18F-FDG  has  been  used  to  assess  the 
migration  and  biodistribution  of  intracoronary  in-
jected bone marrow [29] and peripheral hematopoi-
etic stem cells [30-32] in humans.  18F can also be in-
corporated  into  a  modified  thymidine  analog, 
3’-deoxy-3’-18F-fluorothymidine  (18F-FLT),  which  is 
phosphorylated  by  thymidine  kinase  but  not  incor-
porated into DNA, thus sequestering  18F-FLT within 
the  cell.  18F-FLT  has  been  used  to  visualize  neural 
stem  cell  mobilization  in  the  mouse  hippocampus 
[34].  While  18F-FLT  has  been  used  to  image  tumor 
proliferation  [35],  there  is  evidence  that  this  radio-
tracer  is  not  useful  for  imaging  teratomas  resulting 
from embryonic stem cells [36].  
With  an  increased  half-life,  64Cu  can  offer  a 
longer  duration  of  in vivo  visualization  of  stem  cell 
behavior.  64Cu  can  be  bound  to  an  argi-
nine-glycine-aspartic (RGD) tetramer conjugated with 
the  macrocyclic  chelator  1,4,7,10- 
tetraazacyclododecane-N,N’,N”,  N’’’-tetraacetic  acid 
(DOTA)  to  form  64Cu-DOTA-RGD4.  A  recent  study 
showed the ability of 64Cu-DOTA-RGD4 to target αvβ3 
integrin  to  noninvasively  visualize  teratoma  for-
mation of hESCs in vivo [36]. 64Cu can also be bound to 
a  lipophilic  redox-active  carrier  molecule,  pyru-
valdehyde-bis(N4-methylthiosemicarbazone)  (PTSM). 
64Cu-PTSM has been used to image hESCs differenti-
ated towards renal lineages in fetal rhesus monkeys 
[37] and has been shown to lack adverse cellular ef-
fects [38].  
The most widely used SPECT radionuclides are 
indium-111 (111In), with a half-life of 67 hours, and the 
metastable Technetium-99m (99mTc), with a half-life of 
6 hours. While  111In provides a longer time window 
for cell imaging, 99mTc can be used in higher doses to 
improve  short-term  imaging  resolution.  Several 
groups have used 111In to image in vivo trafficking and 
biodistribution  of  MSCs  around  sites  of  myocardial 
injury in the canine [39, 40] and porcine animal mod-
els  [41].  Human  clinical  studies  have  also  used 
111In-oxine  [31,  42,  43]  and  99mTc-Hexamethylpro-
pleneamine oxine [44-46] to assess stem cell traffick-
ing in acute and chronic myocardial infarction.  
Although both PET and SPECT offer great sensi-
tivity, there are several disadvantages to both tech-
niques,  including  the  leakage  of  radionuclides  into 
non-target cells [47], limited time window for imaging 
due  to  half-life  decay,  lower  spatial  resolution  as 
compared to MRI, and the emission of ionizing radia-
tion that may impair stem cell proliferation and sur-
vival.  However,  in  the  case  of  MSCs,  it  has  been 
shown that free radical scavenging and DNA repair 
mechanisms  are  particularly  robust,  allowing  for 
higher radiotolerance [48].  
4. Optical Reporter Gene Imaging 
Capable of generating long-term signal contrast 
exclusively in live cells, optical reporter gene imaging 
is an extremely powerful tool for understanding stem 
cell biology. Bioluminescence imaging (BLI) involves 
the light-emitting oxidation of exogenously delivered 
substrate D-luciferin by the enzyme firefly luciferase 
(Fluc), which is encoded by the transgenically incor-
porated gene luc of the North American firefly Phon-Theranostics 2012, 2(4) 
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tinus pyralis. Since animal tissues emit negligible visi-
ble light, the signal-to-background ratio and sensitiv-
ity of BLI are very high. Moreover, the signal is not 
only  proportional  to  the  total  number  of  stem  cells 
imaged, which allows for quantitative measurements, 
but  persists  so  long  as  Fluc  is  expressed  and 
D-luciferin is administered, thus facilitating longitu-
dinal monitoring of cell survival. Given its low cost 
and simplicity, BLI has been used extensively in small 
animal studies, including the tracking of hematopoi-
etic stem cell engraftment [49, 50] and the assessment 
of various stem cell types in the murine myocardial 
infarction  model  [51-54].  However,  all  luciferase 
emissions are in the visible spectrum, which is prone 
to  scattering  and  absorption  in  tissue.  Even  firefly 
luciferase,  with  a  comparatively  long  peak  wave-
length of 562 nm, is limited to use in small animals 
due to a maximum penetration of 3 cm in tissue [55].  
 In  contrast  to  BLI,  fluorescence  imaging  (FLI) 
uses an external light source to excite a variety of flu-
orescent compounds, the most common of which is 
green fluorescent protein (GFP). Structurally, GFP is a 
beta  barrel  with  a  centrally  located  tripeptide  se-
quence undergoing cyclization reactions in the pres-
ence  of  oxygen  to  serve  as  the  chromophore  [56]. 
When exposed to blue light at an excitation peak of 
395 nm, the chromophore emits green light at a longer 
peak wavelength of 509 nm due to Stokes shift [56]. 
One of the first studies to employ non-invasive FLI of 
homeostatic  stem  cells  examined  the  skin  stem  cell 
niche in transgenic mice [57]. Imaging with GFP has 
also been used to study the growth and invasiveness 
of  cancer  cells  within  the  microenvironment  of 
hESC-derived teratomas [58] as well as gene expres-
sion in hESCs [59]. Like BLI, FLI is limited by its high 
scattering  and  absorbance  in  mammalian  tissues. 
Although  longer  wavelength  fluorescent  proteins 
may  improve  tissue  penetration  depth,  one  study 
showed that Discosoma red fluorescent protein had a 
negative impact on hematopoietic stem cell survival 
compared to GFP for long-term imaging [60].  
5. Radionuclide Reporter Gene Imaging 
 The best known and most widely used reporter 
gene for both PET and SPECT imaging is the herpes 
simplex  virus  type  1  thymidine  kinase  gene 
(HSV1-tk).  Unlike  mammalian  thymidine  kinase, 
herpes thymidine kinase can phosphorylate two main 
classes of exogenously administered reporter probes: 
pyrimidine  analog  derivatives  such  as 
2′-fluoro-2′-deoxy-β-D-arabinofuranosyl-5-iodouracil 
(FIAU),  and  acycloguanosine  derivatives  such  as 
9-(4-fluoro-3-hydroxy-methyl-butyl)guanine  (FHBG). 
When  herpes  thymidine  kinase  phosphorylates  its 
reporter probe, not only is the probe retained within 
viable cells, but signal amplification also occurs when 
the enzyme reacts with multiple substrates [61].  
To facilitate either PET or SPECT imaging, FIAU 
can be synthesized with the appropriate isotope such 
as positron emitting iodine-124 (124I) or gamma emit-
ting iodine-125 (125I). SPECT imaging with  125I-FIAU 
has been used to detect teratoma formation in mice 
transplanted with hESCs [61]. In terms of PET imag-
ing, FHBG is most commonly used with  18F isotope. 
18F-FHBG has been used to assess tracking and sur-
vival of MSCs in porcine myocardium [62] as well as 
to assess migration of MSCs to tumor stroma [63].  
 Another reporter gene for PET and SPECT im-
aging is the sodium iodide symporter (NIS), a trans-
membrane protein responsible for the uptake of io-
dine in thyroid cells. When expressed in non-thyroid 
cells  through  transfection,  NIS  allows  PET  imaging 
with  124I and SPECT imaging with  123I or  99mTc. NIS 
has  been  used  to  image  in  vivo  cardiac  stem  cell 
transplantation  [64]  as  well  as  MSC  migration  to 
breast cancer tumor stroma, with possible therapeutic 
implications through the use of 131I [65].  
 Advantages  of  radionuclide  reporter  genes  in-
clude its high sensitivity and ability to detect only live 
cells, the possibility of using ganciclovir to comman-
deer HSV1-tk as a suicide gene to mitigate the risks of 
tumorigenicity  [11],  and  the  dual  use  of  NIS  as  an 
imaging and therapeutic tool [65]. Disadvantages in-
clude leakage of radiotracers from labeled cells and 
non-specific uptake by normal tissues [66].  
6. MR Reporter Gene Imaging 
 Of all reporter gene modalities, MRI offers the 
most detailed anatomic and spatial resolution in soft 
tissues. The first MRI reporter gene encoded a creatine 
kinase  enzyme  that  generated  phosphocreatine  de-
tectable  by  31P  magnetic  resonance  spectroscopy 
(MRS) in the rat liver [67]. Since then, four main cat-
egories  of  MRI  reporter  genes  have  emerged.  They 
involve increasing endogenous accumulation of iron 
[68-70],  exploiting  cell  surface  interactions  [71,  72], 
harnessing  enzymatic  reactions  [67,  73,  74],  or  em-
ploying chemical exchange saturation transfer (CEST) 
[75, 76].  
Iron’s effect on T2* field inhomogeneity makes 
the  manipulation  of  intracellular  iron  an  effective 
contrast generation technique. Overexpression of fer-
ritin, for example, causes a compensatory upregula-
tion of transferrin receptors, which in turn increases 
intracellular iron levels. Ferritin reporter genes have 
been used to track porcine cardiac stem cells in the 
murine heart [69] and ESCs in transgenic mice [70]. 
Both studies showed no detrimental effects on stem Theranostics 2012, 2(4) 
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cell differentiation or proliferation.  
Manipulating  cell  surface  interactions  has  also 
shown great potential. The high affinity between bio-
tin and avidin is the strongest non-covalent interac-
tion known to science with a dissociation constant of 
10-15 [71]. A reporter gene encoding for a biotin ac-
ceptor  peptide  can  be  metabolically  biotinylated  by 
endogenous  biotin  ligase  and  expressed  on  the  cell 
surface.  When  exposed  to  exogenously  delivered 
contrast-labeled  streptavidin,  the  cell  can  be  visual-
ized by MRI [71]. Reporter genes for cell surface an-
tigen  can  also  be  used  in  conjunction  with  con-
trast-labeled  antibody.  One  recent  study  employed 
SPIO-labeled  antibody  to  assess  ESC  survival  and 
teratoma formation in the murine heart [72].  
Enzyme-based  reporter  genes  include 
β-galactosidase, which cleaves galactose from specific 
contrast agents to expose the free coordination site of 
gadolinium, and human tyrosinase, which increases 
the  production  of  metal-ion  binding  melanin. 
β-galactosidase has been used with substrate S-GalTM 
for in vivo visualization of bone marrow cells in mice 
[73], and one study used human tyrosinase to image 
breast cancer cells [74]. 
Perhaps the most promising and versatile of all 
MRI  reporter  modalities  is  the  chemical  exchange 
saturation transfer (CEST) technique. Amide protons 
in polypeptides such as poly-L-lysine have a nuclear 
magnetic  resonance  frequency  distinct  from  that  of 
solvent  water  protons,  which  can  be  manipulated 
with  a  radiofrequency  pulse  (RF)  to  perturb  the 
Bolzmann distribution of spins [75]. This perturbation 
is transferred through chemical exchange only to wa-
ter protons that are in chemical equilibrium with the 
CEST  reporter  protein’s  exchangeable  protons  [75]. 
CEST has numerous advantages: its “switchable” na-
ture  in  which  contrast  is  detectable  only  when  the 
radiofrequency pulse is applied; the innocuous bio-
degradable property of the reporter protein; and its 
capability to image multiple anatomic locations using 
different  excitation  frequencies  when  different  con-
trast agents are used. While CEST has been used to 
image rat glioma cells in vivo, this technique has not 
been used in stem cell research to date [71].  
7. Monitoring Survival and Biodistribution 
Maintaining  long-term  survival  and  accurate 
homing of stem cells in animal models must first be 
accomplished before any meaningful clinical applica-
tions in humans can begin. Since direct imaging tech-
niques  are  complicated  by  leakage  of  contrast  and 
persistence of signal in non-viable cells [8, 40], sensi-
tive reporter gene modalities are most appropriate for 
assessing  survival,  whereas  direct  imaging  is  more 
suitable for high resolution detection of cell location 
[9, 76]. The first study to demonstrate reporter gene 
imaging  of  transplanted  cells  showed  that  BLI  and 
18F-FHBG  correlated  with  the  gold  standard  ex vivo 
histopathological  analysis  and  were  feasible  for 
measuring  cell  survival  [77].  However,  subsequent 
studies have shown that very few cells home in on 
and survive in the target organ long-term. One study 
showed  that  eight  weeks  after  transplantation,  less 
than 0.5% of transplanted cardiac stem cells were still 
alive in a rat model of myocardial infarction [52]. An-
other  study  used  BLI  to  compare  the  survival  of 
transplanted bone marrow mononuclear cells (MNs), 
MSCs,  skeletal  myoblasts,  and  fibroblasts  in  the 
mouse  myocardium  and  found  that  although  MNs 
transiently displayed higher survival rates than other 
cell types, the effect was short-lived with only 0.4% of 
MNs  surviving  after  6  weeks  [51].  Furthermore,  in 
vivo analysis of biodistribution showed that a signifi-
cant number of MNs injected into the heart actually 
migrated to the femur, liver, and spleen (Fig. 2) [51]. 
 
 
Figure  2:  In vivo bioluminescence imaging (BLI) in the murine 
myocardial infarction model showing transplanted mononuclear 
cells (MNs) homing in on the heart as well as the femur, spleen, 
and liver (yellow arrows). Skeletal myoblasts (SkMb), mesenchy-
mal stem cells (MSCs), and fibroblasts (fibro) migrate not only to 
the  heart  but  also  to  the  lungs  (red  arrows).  Reprinted  with 
permission from [47]. Theranostics 2012, 2(4) 
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 An additional biodistribution study in humans 
using PET imaging with  18F-FDG showed that only 
1.5% of intracoronary infused peripheral blood mon-
onuclear cells accumulated at the myocardium [30]. 
Multiple  studies  have  investigated  methods  of 
improving stem cell survival and biodistribution, in-
cluding the overexpression of certain genes. In vitro 
studies  have  shown  that  overexpression  of  BCL2 
confers an anti-apoptotic survival benefit to hESCs in 
conditions of stress, such  as serum- and feeder-free 
conditions or single-cell dissociation [78]. An in vivo 
study using BLI showed that overexpression of BCL2 
confers  a  significant  survival  advantage  to  cardio-
myoblasts,  but  only  within  the  first  four  weeks  of 
transplantation  [79].  This  may  be  primarily  due  to 
anti-apoptotic  effects  during  the  early  stresses  of 
transplantation.  Another  study  using  fluorescence 
reporter imaging with GFP showed that overexpres-
sion of CXCR4 in MSCs led to enhanced homing and 
engraftment  in  the  ischemic  myocardium  [80].  The 
cells promoted myoangiogenesis and improved early 
signs of left ventricular remodeling.  
MicroRNAs (miRNAs) can also be used to sup-
press  downstream  pro-apoptotic  genes.  One  study 
using  BLI  showed  that  a  cocktail  of  three  miRNAs 
(miR-21, miR-24, and miR-221) significantly improved 
the  survival  and  engraftment  of  cardiac  progenitor 
cells  in  a  murine  myocardial  infarction  model  [81]. 
Here the BLI signal could be detected for  up to 28 
days and was significantly higher in the cells treated 
with the miRNA cocktail. One proposed mechanism 
for this effect is the downstream suppression of the 
proapoptotic Bim protein.  
A  significant  drawback  to  genetic  overexpres-
sion and or even suppression techniques is the poten-
tial for oncogenic transformation. Hypoxic precondi-
tioning (HP) is therefore an attractive alternative that 
encourages  endogenous  production  of  prosurvival 
factors  such  as  HIF-1α  and  HIF-2α  [82].  One  study 
showed that BLI could be used to assess short-term 
survival of HP-enhanced mesenchymal stromal cells 
[83]. Although the preconditioned cells demonstrated 
increased survival under hypoxic challenge compared 
to  controls,  no  long-term  tracking  was  conducted. 
Future  investigations  into  physiologic  precondition-
ing, using in vivo molecular imaging with longer fol-
low-up times, may help further elucidate the under-
lying mechanisms of stem cell survival and homing. 
In addition, multimodality imaging combining high 
sensitivity PET with high resolution MRI may allow 
not  only  simultaneous  monitoring  of  survival  and 
biodistribution, but also demonstrate clinical applica-
bility. 
8. Monitoring Tumorigenicity  
Pluripotent stem cells share many properties in 
common  with  cancer  cells,  including  self-renewal, 
rapid  proliferation,  lack  of  contact  inhibition,  and 
high telomerase activity [84, 85]. Furthermore, cellular 
manipulations, such as the reprogramming of somatic 
cells  into  iPSCs,  transfection  of  reporter  genes,  and 
overexpression  of  survival  genes,  can  have  unin-
tended tumorigenic side effects. Teratoma formation 
is another concern, along with its potential to degen-
erate  into  malignant  teratocarcinomas  [84].  Given 
these risks, understanding stem cell tumorigenicity is 
of paramount importance for future clinical applica-
tions.  
One study using a double fusion reporter con-
taining Fluc and GFP showed that teratoma formation 
is dependent upon cell number. Assessed over a pe-
riod of eight weeks, a minimum of 1 x 105 intramyo-
cardially injected hESCs were required to form tera-
tomas in mice [86]. Furthermore, a lower threshold of 
1 x 104 cells following hindlimb injection was required 
to  form  teratomas,  providing  insight  into 
niche-dependency (Fig. 3) [82]. Since angiogenesis is 
known to play a major role in tumor growth and de-
velopment, it is important to investigate not only the 
tumor itself but also its supporting stroma. One study 
used  NIS  reporter  imaging  to  show  that  MSCs  ac-
tively home in on growing tumors, where they dif-
ferentiate into vasculature and supporting structures 
[65]. The upregulation of αvβ3 integrin is also known 
to play a role in tumor angiogenesis [87]. One study 
used direct PET imaging with  64Cu-DOTA-RGD4 to 
target αvβ3 integrin, which successfully visualized in 
vivo  hESC  teratoma  formation  in  the  mouse  model 
[36]. These findings show that integrins play a major 
role in teratoma formation and angiogenesis. Moreo-
ver,  PET  imaging  may  have  promising  clinical  ap-
plicability for monitoring tumorigenicity in humans 
because BLI lacks the ability to penetrate deep tissues.  
Due to the risks of teratoma formation, having a 
reporter gene that serves as both an imaging modality 
as well as a fail-safe suicide switch would be highly 
desirable. One study used HSV1-tk PET reporter im-
aging to selectively destroy emerging teratomas with 
the  administration  of  ganciclovir  [11].  Future  direc-
tions for mitigating the risks of tumorigenicity include 
not  only  the  use  of reporter-suicide genes, but also 
vector- and transgene-free reprogramming of somatic 
cells into iPSCs [88, 89] and long-term multimodality 
imaging capable of observing both emerging tumor 
cells and their supporting stroma.  
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Figure 3: Teratoma formation is dependent upon cell number. BLI reveals that a minimum of 1 x 105 human ESCs injected intramyo-
cardially are needed to form teratomas in mice. Reprinted with permission from [82]. 
 
9. Monitoring Immunogenicity 
 Due to limited MHC class I expression and lack 
of MHC Class II expression, ESCs were assumed to be 
“immune privileged” until they were shown to cause 
immune rejection in the mouse model [90]. Although 
the immune response is lower against ESCs than al-
logeneic adult cells, it has been shown that even low 
levels of MHC class I expression can lead to a cyto-
toxic T-cell response [91]. This is exacerbated during 
the process of differentiation and teratoma formation, 
which causes an upregulation of MHC class I mole-
cules  [92].  Not  only  are  ESCs  immunogenic,  more 
recent  evidence  suggests  that  even  iPSCs  can  have 
abnormal gene expression leading to a T-cell medi-
ated immune response in syngeneic mice [93]. There-
fore,  the  immunogenicity  of  all  stem  cell  derived 
therapeutic cells should be rigorously investigated in 
preclinical studies. In small animals, BLI has not only 
been used to confirm the fact that stem cell rejection 
occurs in immunocompetent recipients, but has also 
provided insight into therapeutic strategies to prevent 
rejection.  One  study  used  BLI  to  show  that  trans-
planted xenogeneic human ESCs in immunocompe-
tent  mice  survived  only  7  to  10 days  after  primary 
injection, and only 3 days after repeat transplantation 
[94]. Both cell-mediated and humoral responses were 
shown to be involved, and addition of immunosup-
pressive  therapy  with  sirolimus  and  tacrolimus 
lengthened  survival  to  28  days  [94].  Another  study 
used  BLI  to  demonstrate  that  short-term  immuno-
suppression  with  leukocyte  costimulatory  blockade 
agents allowed long-term engraftment of xenogeneic 
human ESCs and iPSCs (Fig. 4) [95].  
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Figure 4: Longitudinal bioluminescence images of xenogeneic human ESC-transplanted mice that received no treatment, monotherapy, 
or a combination of all three costimulatory blockade agents (COSTIM). Reprinted with permission from [91]. 
 
10. Conclusions 
Before clinical applications in humans, potential 
therapeutic stem cell treatments must undergo exten-
sive scrutiny. Although a great deal of information is 
already  known  about  the  survival,  biodistribution, 
tumorigenicity,  and  immunogenicity  of  pluripotent 
stem  cells,  significant  gaps  in  knowledge  remain. 
Molecular imaging will continue to play a pivotal role 
in answering crucial questions about clinical applica-
tions as well as in helping us understand the under-
lying mechanisms of stem cell biology. Currently, the 
effectiveness of stem cell therapy in terms of both cell 
survival and proper engraftment in animal models is 
far from ideal. With less than 1% of cells surviving or 
correctly  localizing  to  target  tissues,  significant  im-
provement  is  needed  before  meeting  clinical  stand-
ards.  In  that  regard,  hypoxic  preconditioning,  gene 
therapy,  pro-survival  biopolymers,  and  tissue  engi-
neering  represent  promising  techniques  to  improve 
cell survival. However, more in vivo molecular imag-
ing studies must be conducted to confirm long-term 
survival of these cells. The safety of stem cell therapy 
in terms of tumorigenicity and immune rejection must 
also be thoroughly examined. To that end, molecular 
imaging  studies  capable  of  evaluating  the  risk  of 
cancer formation long-term or assessing methods of 
immune  suppression  for  viable  engraftment  are 
highly valuable.  
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